Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 4/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5639756 | 0.92 | BCHE (0.50) | BCHEMAOBCCR3MAPTHTR1A | |
| SCHEMBL5639678 | 0.87 | LMNA (0.41) | BCHEKCNH2CACNA1ILMNATP53 | |
| SCHEMBL5637894 | 0.85 | LMNA (0.39) | BCHEKCNH2CACNA1ILMNATP53 | |
| SCHEMBL5640468 | 0.84 | F10 (0.48) | LMNATP53F10MAPTKMT2A | |
| SCHEMBL4594192 | 0.84 | MAPT (0.53) | BCHELMNAF10MAPTALDH1A1 | |
| SCHEMBL5641350 | 0.84 | F10 (0.52) | KCNH2CACNA1ILMNATP53F10 | |
| SCHEMBL5641674 | 0.84 | BCHE (0.42) | BCHEKCNH2CACNA1ILMNATP53 | |
| SCHEMBL5640959 | 0.83 | F10 (0.51) | F10 | |
| SCHEMBL5642154 | 0.83 | F10 (0.45) | KCNH2CACNA1IF10ALDH1A1 | |
| SCHEMBL4587626 | 0.82 | F10 (0.44) | KCNH2CACNA1IF10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | BCHE 170/4885KCNH2 2181/4885CACNA1I 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.